These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27259818)

  • 1. CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.
    Xu Y; Zhou D; Wang Y; Li J; Wang M; Lu J; Zhang H
    Food Chem Toxicol; 2016 Aug; 94():138-47. PubMed ID: 27259818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
    Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
    Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
    Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
    J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
    Säll C; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Jul; 40(7):1279-89. PubMed ID: 22451699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
    Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
    Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of Organic Anion Transporter 3-Mediated Uptake of Steviol Acyl Glucuronide, a Major Metabolite of Rebaudioside A, with Selected Drugs.
    Zhou D; Xu Y; Wang Y; Li J; Gui C; Zhang H
    J Agric Food Chem; 2020 Feb; 68(6):1579-1587. PubMed ID: 31760750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-
    Katsube Y; Tsujimoto M; Koide H; Hira D; Ikeda Y; Minegaki T; Morita SY; Terada T; Nishiguchi K
    Drug Metab Dispos; 2021 Apr; 49(4):289-297. PubMed ID: 33446524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
    Kudo T; Hisaka A; Sugiyama Y; Ito K
    Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
    Tornio A; Filppula AM; Kailari O; Neuvonen M; Nyrönen TH; Tapaninen T; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2014 Oct; 96(4):498-507. PubMed ID: 24971633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.
    Yu L; Shi D; Ma L; Zhou Q; Zeng S
    Biopharm Drug Dispos; 2013 Jul; 34(5):278-87. PubMed ID: 23536207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
    Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
    Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
    Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
    Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
    Kazmi F; Barbara JE; Yerino P; Parkinson A
    Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.
    Jenkins SM; Zvyaga T; Johnson SR; Hurley J; Wagner A; Burrell R; Turley W; Leet JE; Philip T; Rodrigues AD
    Drug Metab Dispos; 2011 Dec; 39(12):2421-30. PubMed ID: 21911547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism.
    Gan J; Chen W; Shen H; Gao L; Hong Y; Tian Y; Li W; Zhang Y; Tang Y; Zhang H; Humphreys WG; Rodrigues AD
    Br J Clin Pharmacol; 2010 Dec; 70(6):870-80. PubMed ID: 21175442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
    Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
    Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2011 Oct; 39(10):1977-86. PubMed ID: 21778352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.